Amgen's Q3 2007 earnings call highlights continued challenges in the anemia market, particularly with Aranesp experiencing significant US sales declines due to the National Coverage Decision (NCD).  Management expressed confidence in the long-term potential despite short-term headwinds, emphasizing the company's focus on cost containment and continued investment in promising pipeline products like Vectibix, AMG 531, and denosumab, signaling potential for positive stock impacts in the near future .
[1]
